| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/03/2010 | CN100586481C Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 02/03/2010 | CN100586444C Method of processing ginseng for medicinal use and composition |
| 02/02/2010 | US7655802 Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| 02/02/2010 | US7655690 1-sulfonylindole derivatives, their preparation and their use as 5-HT6 ligands |
| 02/02/2010 | US7655688 Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 02/02/2010 | US7655684 1-(Urea-, thiourea- and cyanoguanidine-methylene)benzyl)imidaoles, treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson's disease and Huntington's disease |
| 02/02/2010 | US7655681 Administering zonisamide; clearing mucus; protective patches |
| 02/02/2010 | US7655674 Hedgehog antagonists that inhibit the hedgehog pathway in a smoothened gain-of-function cell with an IC50 within a factor of 20, 10, or even a factor of 5, of the IC50 with which they inhibit the hedgehog pathway in a patched-null cell |
| 02/02/2010 | US7655671 Morphinan derivatives, the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof |
| 02/02/2010 | US7655663 (2S)-4,4-difluoro-1-(2-{[1-(2-pyrazinyl)piperidin-4-yl]amino}acetyl)-2-pyrrolidine carbonitrile; enzyme inhibitors; diabetes |
| 02/02/2010 | US7655657 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1-H-indole tartaric acid salt; nicotinic acetylcholine receptor modulation |
| 02/02/2010 | US7655651 Biphenyl-4-carboxylic acid (4-chloro-3-{7-[4-(2-diethylamino-ethoxy)-phenylamino]-1-methyl-2-oxo-1,4-dihydro-2H-pyrimido[4,5-d]pyrimidin-3-yl}-phenyl)-amide; protein kinase inhibitors |
| 02/02/2010 | US7655647 3-[(1-oxo-2-cyclopropylmethyl-heptyl)]amino-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one; amyloid precursor protein and beta -peptide inhibitor; beta or gamma secretases inhibitor; amyloid plaques and neurofibrillar tangles; neurodegenerative diseases: Alzheimer's disease; Down syndrome |
| 02/02/2010 | US7655619 Insulin-associated peptides with effects on cerebral health |
| 02/02/2010 | US7655616 Traumatic brain and spinal cord injury treatment; administering interleukin-1B converting enzyme (capsase-1) inhibitor |
| 02/02/2010 | US7655463 Treating neuropathic pain, particularly diabetic peripheral neuropathy, by administering a truncated neublastin polypeptide; activating a RET receptor tyrosine kinase |
| 02/02/2010 | US7655460 Nucleic acids encoding sodium channel SCN1A alpha subunit proteins with mutations associated with epilepsy |
| 02/02/2010 | US7655256 Pharmaceutical formulation including a resinate and an aversive agent |
| 02/02/2010 | US7655251 Amphiphilicmonocatenary glycosylated hydrocarbon nitrones; oxidation resistance;free radical scavengers; neuroprotectants; cosmetic products for the skin, hair andnails; imunotherapy; antiinflammatory agents; Alzheimer's disease; Parkinson'sdisease; aging resistance; radiation injuries |
| 02/02/2010 | US7655244 In situ administering to nerve endings by injection or topical |
| 02/02/2010 | US7655231 Methods for treating pain by administering a nerve growth factor antagonist and an NSAID |
| 02/02/2010 | CA2587149C Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds |
| 02/02/2010 | CA2530159C N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
| 02/02/2010 | CA2516682C Imidazol-4-yl-ethynyl-pyridine derivatives |
| 02/02/2010 | CA2507923C Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| 02/02/2010 | CA2494583C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 02/02/2010 | CA2454830C Substituted urea neuropeptide y y5 receptor antagonists |
| 02/02/2010 | CA2442478C Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation |
| 02/02/2010 | CA2418868C 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 02/02/2010 | CA2410305C Preparations comprising combinations of enzyme inhibitors, and the use thereof |
| 02/02/2010 | CA2401832C 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 02/02/2010 | CA2387958C Method of preparing valproic acid compounds |
| 02/02/2010 | CA2324418C Novel opiate compounds, methods of making and methods of use |
| 02/02/2010 | CA2315205C Substituted 2-aryl-4-amino-quinazolines, methods for the prodution ans use thereof as medicaments |
| 02/02/2010 | CA2294809C Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same |
| 02/02/2010 | CA2293724C Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| 02/01/2010 | CA2638190A1 Treatment of als |
| 01/28/2010 | WO2010012004A2 Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
| 01/28/2010 | WO2010011856A2 Stereospecificity of methylsulfinyl reduction |
| 01/28/2010 | WO2010011836A2 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof |
| 01/28/2010 | WO2010011811A2 3-(phenoxyphenylmethyl)pyrrolidine compounds |
| 01/28/2010 | WO2010011626A2 Pyridinyl modulators of ϒ-secretase |
| 01/28/2010 | WO2010011619A1 Large substituent, non-phenolic amine opioids |
| 01/28/2010 | WO2010011570A1 Adamantyl diamide derivatives and uses of same |
| 01/28/2010 | WO2010011548A1 Novel substituted sulfamide derivatives |
| 01/28/2010 | WO2010011546A2 Acyclic compounds having 5-ht6 receptor affinity |
| 01/28/2010 | WO2010011331A2 Compositions and methods related to sirt1 function |
| 01/28/2010 | WO2010011315A2 Proteins for use in diagnosing and treating infection and disease |
| 01/28/2010 | WO2010011154A1 Methods for identifying biomarkers, therapies and compounds suitable for the treatment of depression and schizophrenia and pharmaceutical compositions thereof and development of drugs targeting a newly discovered cns arachidonic acid pathway of anhedonia |
| 01/28/2010 | WO2010011147A1 Indole compounds |
| 01/28/2010 | WO2010010935A1 Optically active heterocyclidene-n-arylacetamide derivative |
| 01/28/2010 | WO2010010934A1 Heterocyclidene derivative having p-substituted arylacetamide |
| 01/28/2010 | WO2010010933A1 Heterocyclidene-n-(3,4-dihydro-2(1h)-quinazolin-5-yl) acetamide derivative |
| 01/28/2010 | WO2010010908A1 Therapeutic agent for migraine |
| 01/28/2010 | WO2010010797A1 Pharmaceutical composition comprising dyrk-inhibiting compound |
| 01/28/2010 | WO2010010458A1 Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
| 01/28/2010 | WO2010010288A2 Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof |
| 01/28/2010 | WO2010010223A1 Use of microparticles containing genetically modified cells in the treatment of neurodegenerative diseases |
| 01/28/2010 | WO2010010138A1 Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease |
| 01/28/2010 | WO2010010136A1 Pharmaceutical composition comprising pramipexole and an anti-inflammatory agent for the treatment of parkinson's disease |
| 01/28/2010 | WO2010010133A1 2-thia-1,3-diazaspirocyclic-substituted phenylacetamides as glt1 mediators for neurological diseases |
| 01/28/2010 | WO2010010112A2 Construct and method for the internalization of cargo molecules into a cell |
| 01/28/2010 | WO2010010106A1 Aminophosphinic derivatives that can be used in the treatment of pain |
| 01/28/2010 | WO2010010080A1 Aryl-sulphonamidic dimers as metalloproteases inhibitors |
| 01/28/2010 | WO2010010014A1 4,5-dihydro-oxazol-2-yl derivatives |
| 01/28/2010 | WO2010009557A1 Tissue kallikrein for the treatment of parkinson's disease |
| 01/28/2010 | WO2009147441A3 Novel treatments |
| 01/28/2010 | WO2009145357A8 Benzo [1, 4] diazepines substituted at the 1-position by a ring, for use as antidepressants |
| 01/28/2010 | WO2009140665A3 Identification of a molecular signature for antipsychotics and serms |
| 01/28/2010 | WO2009136396A3 Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases |
| 01/28/2010 | WO2009123714A3 Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| 01/28/2010 | WO2009118753A3 Process for preparation of naratriptan hydrochloride |
| 01/28/2010 | WO2009114539A9 Neuroprotective integrin-binding peptide and angiopoietin-1 treatments |
| 01/28/2010 | WO2009101018A3 3-alkyl-piperazine derivatives and uses thereof |
| 01/28/2010 | WO2009009768A8 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS |
| 01/28/2010 | US20100022783 Cyclohexanecarboxylic acid compound |
| 01/28/2010 | US20100022659 Methods and Compositions for the Treatment of CNS-Related Conditions |
| 01/28/2010 | US20100022658 Methods for treating cognitive impairment in humans |
| 01/28/2010 | US20100022653 Process for the Preparation of and Crystalline Forms of Optical Enantiomers of Modafinil |
| 01/28/2010 | US20100022650 Benzamide Derivatives As EP4 Receptor Agonists |
| 01/28/2010 | US20100022645 PKC-Activating Compounds for the Treatment of Neurodegenerative Diseases |
| 01/28/2010 | US20100022643 Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| 01/28/2010 | US20100022637 Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof |
| 01/28/2010 | US20100022633 Cognitive abilities improving agent |
| 01/28/2010 | US20100022628 Alternative oxidase and uses thereof |
| 01/28/2010 | US20100022620 Epitope reduction therapy |
| 01/28/2010 | US20100022616 3-(phenoxyphenylmethyl)pyrrolidine compounds |
| 01/28/2010 | US20100022614 Pharmaceutical composition for external application and adhesive skin patch |
| 01/28/2010 | US20100022611 1,5-Diaryl-Pyrazoles As Cannabinoid Receptor Neutral Antagonists Useful As Therapeutic Agents |
| 01/28/2010 | US20100022610 New Crystalline Forms |
| 01/28/2010 | US20100022603 Peroxisome proliferator-activated receptor agonists; insulin resistance; metabolic diseases; diabetes; dyslipidemia; 2-Ethoxy-N-[5-(5-isopropyl-[1,3,4]thiadiazol-2-ylsulfamoyl)-indan-2-yl]-4-trifluoromethyl-benzamide |
| 01/28/2010 | US20100022594 thiophene sulfonamide derivatives such as 5-Chloro-N-[(S)-2-hydroxy-1-phenylethyl]thiophene-2-sulfonamide, that inhibit the production of beta amyloid protein from amyloid precursor protein; capable of passing through the blood-brain barrier, used for treatment of Alzheimer's disease and Down's syndrome |
| 01/28/2010 | US20100022583 PYRIDINYL MODULATORS OF gamma-SECRETASE |
| 01/28/2010 | US20100022581 Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| 01/28/2010 | US20100022580 New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof |
| 01/28/2010 | US20100022574 Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist |
| 01/28/2010 | US20100022571 Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors |
| 01/28/2010 | US20100022567 Compositions containing pufa and/or uridine and methods of use thereof |
| 01/28/2010 | US20100022560 Thiophene pyrazolopyrimidine compounds |
| 01/28/2010 | US20100022555 Novel Derivatives |